Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Deborah Collyar: What's In It for Patients?

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Deborah Collyar: What's In It for Patients?

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Matthew Seymour, MD: A Clinical Trialist’s Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Potential New Second-Line Standard of Care Emerges in Small Cell Lung Cancer

Protease Activator Approved by the FDA for Diffuse Midline Glioma

RCC Genetic Testing Key to Avoiding Misdiagnosis of Rare Subtypes

Two ACS Studies Show Colorectal Cancer Screening and Early Diagnosis Have Soared in Adults Aged 45 to 49 Years

Nivolumab Plus Ipilimumab in Advanced Ovarian and Endometrial Clear Cell Cancers